EPHA2 and glioblastoma: A phase 1 study examined the side effects and best dose of DOPC-encapsulated EphA2 siRNA in the treatment of patients with metastatic solid tumors or recurrent GBM and demonstrated that this compound is able to slow the growth of tumor cells (NCT01591356).